Abstract
Abstract Over half of all cancer patients will receive a platinum drug during their treatment. Recent interest in our labs involve exploiting the high affinity of a discrete class of platinum-based anticancer agents, polynuclear platinum complexes (PPCs), for sulfated glycosaminoglycans (sGAGs). sGAGs are increasingly seen as potential biomarkers and molecular targets in many forms of cancer. sGAG expression levels were quantified in patient derived xenograft (PDX) and cellular models of triple negative breast cancer (TNBC) and ovarian cancer. PPCs, but not carboplatin, show increased levels of tumor uptake and efficacy in models expressing high levels of sGAGs. sGAGs may provide a viable target for PPCs, producing a significant advantage over clinical platinum agents in this setting. Citation Format: Jennifer E Koblinski, Erica J Peterson, James D. Hampton, J Chuck Harrell, Nicholas P Farrell. Toward precision medicine for platinums [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2019 Oct 26-30; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2019;18(12 Suppl):Abstract nr C068. doi:10.1158/1535-7163.TARG-19-C068
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
